FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare
Related Topics >> GlaxoSmithKline | Tykerb

Tykerb - 2007 FDA approvals

January 8, 2008 — 3:54pm ET | By Maureen Martino
Tools

Drug: Tykerb (lapatinib)
Indication: Metastatic breast cancer
Company: GlaxoSmithKline
Approval Date: March 13, 2007

Scoop: The FDA gave its approval to Tykerb for metastatic breast cancer in combination with Xeloda. Tykerb is also in trials for metastatic brain cancer. Tykerb has an advantage over the blockbuster Herceptin because it is administered in pill form while Herceptin is injected. And data supports that Tykerb in combination with Xeloda is more effective that a treatment consisting only of Xeloda.

More news:
FDA approves Tykerb for breast cancer. Report

Previous: TekturnaIndexNext: Soliris
Bookmark and Share
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about GlaxoSmithKline   Tykerb  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.